[Myocardiopathy from a new anthracyclic derivative (author's transl)].
A 58-year-old man with subcutaneous metastases from a naevocarcinoma was prescribed 1 138 mg/m2 of a new anthracylic derivative, dietoxy-acetoxy-daunorubicine, at doses of 180 mg every three weeks. Irreversible cardiac failure occurred nine months after starting treatment, and was considered to be due to the toxic effects of the compound. He improved for a short period after very high doses of vasodilatators but death occured very shortly afterwards. Histological examination revealed severe subendocardial fibrosis, disseminated interstitial fibrosis, and degenerative and necrotic lesions of the myocytes. The authors discuss the factors involved in the cardiotoxicity of the anthracyclines: total dose, intervals between doses, associated risk, factors (age, radiotherapy). Even at usual doses signs of myocardial dysfunction are found in one third of patients treated, with the presence of histological lesions in all these cases, but clinical cardiac failure is rarely observed.
D009202:Cardiomyopathies / Q000139:chemically induced* / Q000473:pathology; D003630:Daunorubicin / Q000009:adverse effects / Q000031:analogs & derivatives* / Q000627:therapeutic use; D006333:Heart Failure / Q000139:chemically induced* / Q000473:pathology; D006801:Humans; D008297:Male; D008545:Melanoma / Q000188:drug therapy; D008875:Middle Aged; D009206:Myocardium / Q000473:pathology; D012878:Skin Neoplasms / Q000188:drug therapy
C017218:detorubicin; D003630:Daunorubicin
Myocardiopathie due à un nouveau dérivé anthracyclique. Aspect anatomo-clinique.